UY31772A - Asociación de la dronedarona con al menos un diurético, su aplicación en terapéutica. - Google Patents

Asociación de la dronedarona con al menos un diurético, su aplicación en terapéutica.

Info

Publication number
UY31772A
UY31772A UY0001031772A UY31772A UY31772A UY 31772 A UY31772 A UY 31772A UY 0001031772 A UY0001031772 A UY 0001031772A UY 31772 A UY31772 A UY 31772A UY 31772 A UY31772 A UY 31772A
Authority
UY
Uruguay
Prior art keywords
diuretic
therapeutics
association
application
dronedarona
Prior art date
Application number
UY0001031772A
Other languages
English (en)
Inventor
Radzik David
Van Eickels Martin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39684441&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31772(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY31772A publication Critical patent/UY31772A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Asociación de dronedarona o una de sus sales farmacéuticamente aceptables con al menos un diurético, su aplicación en terapéutica.
UY0001031772A 2008-04-17 2009-04-17 Asociación de la dronedarona con al menos un diurético, su aplicación en terapéutica. UY31772A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0802128A FR2930149B1 (fr) 2008-04-17 2008-04-17 Association de dronedarone avec au moins un diuretique, son application en therapeutique
US4599908P 2008-04-18 2008-04-18

Publications (1)

Publication Number Publication Date
UY31772A true UY31772A (es) 2009-12-14

Family

ID=39684441

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031772A UY31772A (es) 2008-04-17 2009-04-17 Asociación de la dronedarona con al menos un diurético, su aplicación en terapéutica.

Country Status (26)

Country Link
US (1) US20110136899A1 (es)
EP (1) EP2280700A2 (es)
JP (1) JP2011517694A (es)
KR (1) KR20110005245A (es)
CN (1) CN102065856A (es)
AR (1) AR071326A1 (es)
AU (1) AU2009241966A1 (es)
BR (1) BRPI0910559A2 (es)
CA (1) CA2721560A1 (es)
CL (1) CL2009000918A1 (es)
CO (1) CO6300842A2 (es)
CR (1) CR11735A (es)
DO (1) DOP2010000308A (es)
EA (1) EA201071203A1 (es)
EC (1) ECSP10010552A (es)
FR (1) FR2930149B1 (es)
IL (1) IL208749A0 (es)
MA (1) MA32355B1 (es)
MX (1) MX2010011401A (es)
NI (1) NI201000171A (es)
PE (1) PE20091808A1 (es)
SV (1) SV2010003702A (es)
TW (1) TW200951117A (es)
UY (1) UY31772A (es)
WO (1) WO2009133310A2 (es)
ZA (1) ZA201007390B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2280701A2 (en) 2008-04-17 2011-02-09 Sanofi-Aventis Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868179A (en) * 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
US4988513A (en) * 1990-01-09 1991-01-29 Monsanto Company Method of treating hypokalemia
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US6411840B1 (en) * 1999-11-16 2002-06-25 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation
FR2803846B1 (fr) * 2000-01-17 2002-04-05 Clariant France Sa 3-(1-hydroxy-pentylidene)-5-nitro-3h-benzofuran-2-one, son procede de preparation et son utilisation
FR2817864B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
FR2817865B1 (fr) * 2000-12-11 2005-02-18 Sanofi Synthelabo Derive aminoalkoxybenzoyle sous forme de sel, son procede de preparation et son utilisation comme intermediaire de synthese
EP1347756B1 (en) * 2000-12-27 2006-03-08 Genzyme Corporation Controlled release of anti-arrhythmic agents from a biodegradable hydrogel for local application to the heart
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US20030229007A1 (en) * 2002-05-30 2003-12-11 Roberto Levi Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
DE10237819A1 (de) * 2002-08-19 2004-03-04 Bayer Ag 5-Nitrobenzofurane
US20050004194A1 (en) * 2003-05-15 2005-01-06 Graves Kurt Chum Use of organic compounds
US20060093673A1 (en) * 2003-06-27 2006-05-04 Coury Arthur J Controlled release of anti-arrhythmic agents
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7772232B2 (en) * 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US20070248564A1 (en) * 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
US20090076137A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dronedarone
EP2280701A2 (en) * 2008-04-17 2011-02-09 Sanofi-Aventis Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
EP2133075A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion
EP2133074A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
EP2153830A1 (en) * 2008-08-07 2010-02-17 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en) * 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Also Published As

Publication number Publication date
JP2011517694A (ja) 2011-06-16
CN102065856A (zh) 2011-05-18
MX2010011401A (es) 2011-03-02
US20110136899A1 (en) 2011-06-09
CR11735A (es) 2010-11-22
CO6300842A2 (es) 2011-07-21
AR071326A1 (es) 2010-06-09
CA2721560A1 (fr) 2009-11-05
BRPI0910559A2 (pt) 2015-09-22
CL2009000918A1 (es) 2010-06-11
SV2010003702A (es) 2011-03-04
FR2930149B1 (fr) 2011-02-18
DOP2010000308A (es) 2010-11-30
WO2009133310A3 (fr) 2009-12-23
NI201000171A (es) 2012-01-23
MA32355B1 (fr) 2011-06-01
ECSP10010552A (es) 2010-11-30
EP2280700A2 (fr) 2011-02-09
AU2009241966A1 (en) 2009-11-05
FR2930149A1 (fr) 2009-10-23
TW200951117A (en) 2009-12-16
PE20091808A1 (es) 2009-12-03
ZA201007390B (en) 2012-01-25
EA201071203A1 (ru) 2011-06-30
IL208749A0 (en) 2010-12-30
KR20110005245A (ko) 2011-01-17
WO2009133310A2 (fr) 2009-11-05

Similar Documents

Publication Publication Date Title
CL2009001263S1 (es) Maquina de afeitar.
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
RS53124B (en) USE OF BETANECOL FOR THE TREATMENT OF XEROSOMOMY
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
RS53586B1 (en) DERIVATION OF DECISION
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
CL2011000268A1 (es) Uso de dronedarona para preparar un medicamento util en la prevencion del ictus o ataque isquemico transitorio.
DOP2010000308A (es) Asociacion de la dronedarona con al menos un diuretico, su aplicacion en terapeutica
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
BRPI0920878A2 (pt) inbidor de ksp161 para aumentar apoptose, sua administração e seu uso.
CL2009001973S1 (es) Mostrador.
BR112012002311A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0913586A8 (pt) combinação, e, uso de uma combinação.
JP2012513655A5 (es)
BRPI0911622A2 (pt) derivados de benzoxepina e benzociclo-heptano.
RS53014B (en) 4R, 5S-ENANTIOMER 2- (5-METHYL-2-OXO-4-PHENYL-PYROLIDIN-1-IL) -ACETAMIDE WITH NOOTROPIC ACTIVITY
FR2926132B1 (fr) Arc monolithique.
IT1396928B1 (it) Faccetta dentale in ceramica modificata, di ridotto spessore.
UA38873U (en) 8-n-(furyl-2)methylamino-1-n-chlorobenzyl theobromin having diuretic, anti-inflammatory and antioxidant action
CL2008000267S1 (es) Perfil.
CL2008000265S1 (es) Perfil.
CL2008000260S1 (es) Perfil.
CL2008000256S1 (es) Perfil.
CL2008000276S1 (es) Perfil.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140602